BridgeBio Oncology Therapeutics (BBOT)
Zuhui Zhang currently serves as Associate Director of Medicinal Chemistry at BridgeBio Oncology Therapeutics since May 2024, having held similar positions at BridgeBio from July 2021 to May 2024 as both Associate Director and Principal Scientist. Prior experience includes a Senior Scientist role in Medicinal Chemistry at FibroGen, Inc. from August 2017 to July 2021, and earlier positions as a Scientist at NewLink Genetics and Research Scientist at the University of South Florida. Educational qualifications encompass a PhD in Organic Chemistry from the University of Science and Technology of China and a Bachelor's degree in Chemistry from Anhui University. Noteworthy contributions include the design and synthesis of bioactive molecules, as well as significant advancements in organic synthesis methodologies during academic research.
This person is not in any teams
BridgeBio Oncology Therapeutics (BBOT)
BridgeBio Oncology Therapeutics is a clinical-stage biopharmaceutical company advancing a next generation pipeline of novel small molecule therapeutics targeting RAS and PI3K malignancies. Initially formed as a subsidiary of BridgeBio, BridgeBio Oncology Therapeutics completed a $200M private financing with external investors in 2024 with the goal of improving outcomes for patients with cancers driven by the two most prevalent oncogenes in human tumors.